U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chao YS, Clark M, Carson E, et al. HPV Testing for Primary Cervical Cancer Screening: A Health Technology Assessment [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Mar. (CADTH Optimal Use Report, No. 7.1b.)

Cover of HPV Testing for Primary Cervical Cancer Screening: A Health Technology Assessment

HPV Testing for Primary Cervical Cancer Screening: A Health Technology Assessment [Internet].

Show details

Objectives

The objective of this health technology assessment (HTA) is to address the policy question by assessing the DTA, clinical utility, safety, cost-effectiveness, patients’ experiences and perspectives, ethical issues, and implementation issues of HPV testing as a primary screening tool for cervical cancer screening. This HTA will be conducted to inform decisionmaking, policy development, capacity planning, and recommendations around primary HPV-based testing for cervical cancer screening.

Research Questions

The HTA addressed the following research questions. For the purposes of this HTA, the diagnostic efficacy of primary HPV testing as a primary screening tool for cervical cancer includes evidence regarding the DTA and clinical utility (including safety and other clinical outcomes) of that screening strategy. Details on the specific interventions and outcomes are included in Table 1.

  1. What is the diagnostic efficacy of primary high-risk HPV testing, with or without cytology triage, compared with primary cytology-based testing for asymptomatic cervical cancer screening?
  2. What are the diagnostic efficacies of primary high-risk HPV testing strategies compared with each other for asymptomatic cervical cancer screening?
  3. What is the comparative cost-effectiveness of primary high-risk HPV testing, with or without cytology triage, compared with primary cytology-based testing for asymptomatic cervical cancer screening Canada?
  4. What are the perspectives of adults eligible for cervical cancer screening, their family members, and their caregivers regarding the value and impact of HPV testing for cervical cancer screening on their health, health care, and lives?
  5. What ethical issues are raised by HPV testing for cervical cancer screening and how might they be addressed?
  6. What are the main challenges, considerations, and enablers to implementing HPV testing for primary cervical cancer screening in Canada?

Separate reviews and analyses have been conducted to address each research question. Each is presented in a separate chapter that outlines the specific research methods used and results.

Copyright © 2019 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK543109

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (8.2M)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...